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MINIMAL RESIDUAL DISEASE PRIOR TO AUTOLOGOUS STEM CELL
TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKE-
MIA AS A PREDICTOR OF RELAPSE
Rojas, A.M.1, Song, S.X.2, Corliss, A.1, Truell, J.2, Paquette, R.L.1,
Schiller, G.J.1, Territo, M.C.1 1UCLA Medical Center, Los Angeles,
CA; 2UCLA Medical Center, Los Angeles, CA.
The level of minimal residual disease (MRD) after consolidation
has been reported in the past as being a strong predictor of relapse in
patients treated with standard chemotherapy. We evaluated the
presence ofMRD in our adult patients with acute myelogenous leu-
kemia (AML) after consolidation and just prior to autologous stem
cell transplant. A total of 47 patients underwent autologous stem
cell transplant for AML from June, 2002 through December,
2004. All patients were in first complete remission and had achieved
this remission after induction chemotherapy using cytarabine and
idarubicin, with the standard 71 3 regimen followed by one course
of consolidation with mitoxantrone and high dose cytarabine. All
patients had bone marrow obtained 2–4 weeks prior to transplant
and were in complete remission as defined by morphology. Data
were available on 42 of these patients to look for MRD by multi-
parametric flow cytomety at a sensitivity level of 0.5 to 1%. Out
of these 42 patients, 15 (36%) had documented MRD detected on
bone marrow biopsy prior to transplant. All 15 of the patients
have relapsed and died. Of the 27 patients who did not have evi-
dence ofMRDgoing into transplant, 14 have relapsed.Thus despite
lack of evidence of MRD, using our past techniques, relapse was
seen in 52% of these patients. At this time we are in the process
of evaluating a subsequent group of patients who underwent autol-
ogous stem cell transplant using a more sensitive assay for MRD. In
conclusion, in spite ofmorphologic complete remission, evidence of
MRD after consolidation and prior to autologous stem cell trans-
plant was predictive of relapse. In the future, alternative treatment
approaches should be considered for such patients.156
TREATMENT OF MYELOID MALIGNANCIES IN ELDERLY PATIENTS WITH
FLUDARABINE AND TARGETED BUSULFAN (t-Bu) AND ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Fernandez, H.F., Henao-Uribe, A.M., Poling, W.H., Chavez, J.C.,
Alsina, M., Ayala, E., Field, T., Kharfan-Dabaja, M., Perez, L.,
Raychaudhuri, J., Ochoa-Bayona, L., Anasetti, C. H Lee Moffitt Cancer
Center and Research Institute, Tampa, FL.
Despite the poor prognosis of elderly patients with standard che-
motherapy, concerns with intensive conditioning regimens have lim-
ited the use of allogeneic HCT in this population. Reduced intensity
regimes have emerged as an option for these patients. We treated
twenty patients over the age of 60 with fludarabine and targeted bu-
sulfan (t-Bu). The median busulfan AUC received was 5244 mmol/
min. Graft versus host disease (GVHD) prophylaxis consisted in ta-
crolimus andmethotrexate (75%) and tacrolimus andmycophenolate
mofetil (25%).Median age was 64.8 (60–69) years. Eleven were male
(55%) and nine female (45%). Six patients (30%) had de novo AML,
ten (50%) secondary AML and four (20%) high risk MDS. Five pa-
tients (25%) had high-risk disease in first complete remission
(CR1) and five (25%) had AML in second complete remission
(CR2). Ten patients were not in remission at the time of transplant.
Donor sources included six (30%) HLA-matched siblings, 13
(65%)matchedunrelated andone (5%)mismatchedunrelateddonor.
A high Sorror Comorbidity Index (.3 points) was found in 35% of
patients. Acute GVHD occurred in all the patients (65% Grade I/
II, 35% grade III/IV). The median follow-up of survivors was 731
days (113–11491). Non-relapse mortality was 10%. Relapse rate at
365 days was 45%. Disease-free (DFS) and overall survival (OS) at
365 days were 50.91/-12% and 61.301/-12% respectively.
Conclusion: Given the sub-optimal results of standard chemo-
therapy in this patient population and the low transplant related
mortality and encouraging OS seen in our cohort, targeted RIC al-
logeneic HSCT should be considered as a feasible alternative in pa-
tients older than 60 years with high risk MDS/AML. Further study
in this group is warranted.157
THERAPEUTIC CHOICES IN PATIENTS WITH PH1 (1) CHRONIC MYE-
LOGENOUS LEUKEMIA LIVING IN DEVELOPING COUNTRIES IN THE
TYROSINE KINASE INHIBITORS (TKI) ERA: STEM CELL TRANSPLANTA-
TION OR TKI?
Ruiz-Arguelles, G.J.1,2, Tarin-Arzaga, L.C.3, Gonzalez-
Carrillo, M.L.2, Gutierrez-Riveroll, K.I.1, Rangel-Malo, R.2, Gutier-
rez-Aguirre, C.H.3, Cantu-Rodriguez, O.G.3, Gomez-Almaguer, D.3,
Giralt, S.4 1Centro de Hematologia y Medicina Interna de Puebla, Pue-
bla, Mexico; 2Laboratorios Clinicos de Puebla, Puebla, Mexico; 3Hospital
Universitario, Monterrey, Nuevo Leon, Mexico; 4MD Anderson Cancer
Center, Houston, TX.
Seventy two patients with Ph1 (1) chronic myelogenous leuke-
mia (CML) in a first chronic phase were followed during a 6-year
period in two different institutions in Mexico. Twenty two of
them were given a reduced-intensity allogeneic stem cell transplan-
tation, whereas 50 were treated with a tyrosine kinase inhibitor
(TKI), mainly imatinib mesylate. The two groups were balanced
in their salient features and the overall results of the treatment
were statistically similar: The six-year overall survival (SV) for pa-
tients given an allograft was 77% and for patients given a TKI
was 84% (p NS); whereas the median survival for both groups has
not been reached, being above 71 and 90 months respectively (p
NS). Most of the patients (91%) who were allografted elected this
treatment because they were unable to afford the treatment with
a TKI, whereas most of those treated with a TKI (84%) were given
the treatment through institutions devoted to support the treatment
of such individuals; only 16%were able to afford the treatment with
TKI. Themedian cost of each allograft was 18 000USD, an amount
which is useful to afford 180 days of treatment with imatinib (400
mg/day) in Mexico. Despite the fact that drug treatment is superior
to allografting as first-line therapy in CML in chronic phase in de-
veloped countries, stem cell transplantation has still a relevant role
in circumstances of limited resources. Cost considerations favor al-
logeneic stem cell transplantation as a one-in-a-life-time procedure
in which lifelong drug treatment with an expensive drug represents
an excessive burden on resources.158
RELAPSE OF ACUTE MYELOID LEUKMIA AFTER ALLOGENEIC STEM-
CELL TRANSPLANTATION (SCT)WITHMYELOABLATIVE CONDITIONING
IS ASSOCIATED WITH LONGER SURVIVAL THAN RELAPSE AFTER RE-
DUCED-INTENSITY CONDITIONING (RIC)
Shimoni, A., Hardan, I., Shem-Tov, N., Rand, A., Ribakovsky, E.,
Yerushalmi, R., Nagler, A. Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
Relapse of AML/MDS after allogeneic SCT is associated with
poor outcome. A subset of patients (pts) can be salvaged with DLI
or with a second SCT. It was previously speculated that pts given
RIC may have a better chance to be salvaged than pts failing
high-dose conditioning. We retrospectively analyzed results of
171 SCTs for AML/MDS with iv busulfan (ivBu)-based regimens.
58 pts were eligible for myeloablative conditioning and were given
standard ivBuCy. 57 were given RIC consisting of fludarabine (F)
and ivBu (FB2, 6.4 mg/kg) and 56 were given a modifiedmyeloabla-
tive conditioning consisting of F and full-dose ivBu (FB4, 12.8 mg/
kg). Median age was 40 (17–64), 60 (43–75) and 52 (18–66) years,
respectively (p \ 0.001). 56% had active leukemia at SCT and
47% had unrelated donors with no difference between the regi-
mens. With a median follow-up of 31 months (4–90), 70 pts re-
lapsed, 20 after BuCy, 25 after FB2, and 25 after FB4, cumulative
incidence 38%, 49% and 48%, respectively (p5NS). The median
time to relapse was 5.3 (1–59), 3.4 (1–34) and 2.7 (1–30) months, re-
spectively (p5NS); 65%,60% and 64% of all relapses occurred
within 6 months of SCT, while 20%, 12% and 8% occurred after
more than 2 years, respectively (p5NS). 25 pts were treated with
immune-suppression withdrawal alone, 12 were given DLI with
or without preceding low-dose chemotherapy, 33 were given inten-
sive therapy either salvage chemotherapy followed by mobilized
DLI (n 5 24) or a second SCT (n 5 9, 5 from a different donor).
Treatment types were not significantly different among the
60 Poster Session Iregimens.With amedian follow-up of 15months from relapse (0.5–
52), 12 pts are alive, 9 in remission. The most important predicting
factor for survival after relapse was the duration of remission. Pts re-
lapsing . 6 months and\ 6 months after SCT had a median sur-
vival of 7.2 and 1.4 months and estimated 2-year survival of 22%
and 2%, respectively (p \ 0.001). Survival rates were 20%, 0%
and 4% after BuCy, FB2 and FB4, respectively (p 5 0.04). SCT
in refractory disease was also predictive of poor outcome after re-
lapse (p\0.001).Multivariable analysis determined short remission
after SCT and conditioning with FB regimens as independent ad-
verse factors with hazard ratios of 3.3 (1.9–6.3, p\ 0.001) and 2.0
(1.0–4.0, p 5 0.04), respectively. In conclusion the notion that pts
given RIC can be salvaged more easily if they relapse is not substan-
tiated and should not be a rationale to select RIC overmyeloablative
conditioning.159
FEASIBILITY OF CLOFARABINE CYTOREDUCTION BEFORE INITIATION
OF ALLOGENEIC STEM CELL TRANSPLANT REGIMEN DURING THE CY-
TOPENIC PHASE FOR PATIENTS WITH REFRACTORY ACUTE MYELOGE-
NOUS LEUKEMIA
Locke, F.L., Artz, A.S., Rich, E.S., van Besien, K., Stock, W. The Uni-
versity of Chicago, Chicago, IL.
Patients with refractory leukemia entering allogeneic stem cell
transplant (Allo-SCT) fare poorly, and higher disease burden corre-
lates with decreased disease free survival (DFS) (van Besien, JCO
2005). To determine the feasibility of clofarabine (CLO) cytoreduc-
tive therapy as a bridge to Allo-SCT we retrospectively analyzed 14
heavily pretreated refractory acute myelogenous leukemia (AML)
pts. All pts received CLO 30–40 mg/m2 intravenous daily for five
consecutive days as bridging therapy with the intention to initiate
Allo-SCT conditioning during the cytopenic phase, 14–21 days
later. Pts had a mean of 2.2 prior treatment regimens, and 8 had pri-
mary refractory leukemia. 4 pts were relapsed following a prior stem
cell transplant (1 autologous and 3 Allo-SCT).
To assess CLO cytoreduction, bone marrow (BM) biopsy and as-
pirate were performed at the nadir, day 12 after CLO. Cytoreduc-
tion was defined as post CLO marrow with\20% cellularity and
\10% blasts. CLO achieved cytoreduction in 8/14 pts. Themedian
BM cellularity was 45% (4–90%) before and 5% (1–83%) after
CLO. The median BM blast % was 23% (10%-100%) before and
6% (0%-90%) after CLO.
Of the 14 pts, 13 proceeded to Allo-SCT by day 26 (median 22,
range 17–26). 7 pts received a fludarabine, busulfan, campath regi-
men; 5 pts received fludarabine, melphalan with either ATG (2) or
Campath (3); 1 pt received a TBI-based regimen. Grade 4 hyperbi-
lirubinemia prevented one pt from proceeding to Allo-SCT prepar-
ative regimen.
Of the 13 pts receiving Allo-SCT the median follow up is 15
months for survivors. 3 pts are alive and disease free at 4.3, 16.5,
and 40 months after Allo-SCT, and all achieved CLO cytoreduc-
tion. 2 pts are alive with progressive disease at 8 and 15 months.
The overall DFS at day 100 was 9/13. 3 pts relapsed before day
100, 2 of whom did not achieve cytoreduction. Beyond day 100
an additional 3 pts relapsed at 5.5, 5.5, and 6.5 months. 1 pt died
of treatment related motality (TRM), sepsis, at day 17. The TRM
at day 100 was 1/13, and 4/13 at one year.
In conclusion, 13/14 patients with refractory AML were able to
undergo Allo-SCT with acceptable TRM in this heavily pretreated
group after CLO re-induction. Based on these data, we are pursuing
a prospective feasibility study of CLO cytoreduction followed by
Allo-SCT during the cytopenic phase.160
PLASMA AND CSF PHAMACOKINETICS (PK) AND RESPONSE TO DASATI-
NIB IN A YOUNG CHILDWITH RELAPSING Ph1 ALL AFTER ALLOGENEIC
TRANSPLANT
Morris, C.L.1, Brown, W.C.2, Zappia, J.3, Morris, J.1 1Loma Linda
University Medical Center, Loma Linda, CA; 2Loma Linda University
Medical Center, Loma Linda, CA; 3Loma Linda University Medical
Center, Loma Linda, CA.Background: Dasatinib is a second-generation abl tyrosine ki-
nase inhibitor approved for patients with imatinib-intolerant or re-
sistant CML and Ph1 ALL. Plasma PK has not been studied in
children or CSF.Methods: Prospective analysis of dasatinib plasma
andCSF levels and clinical response in an 8-year-oldmale with Ph1
ALL in relapse (diagnosed at age 6 y). Serum and CSF levels were
determined by liquid chromatography tandem mass spectrometry
with a detection limit of 1 ng/ml. Results: The patient received
an unrelated donor stem cell transplant in 1st remission and a second
transplant following relapse 6 mo later. He received Imatinib 300
mg po QD (15 mg/kg) during consolidation, maintenance, and fol-
lowing his 1st transplant.Hedeveloped headache, leg pain, and a sin-
gle skin nodule of leukemia 7 mo after his last transplant. CSF had 7
blasts/ul, head CT showed hyper-intense chloromas in frontal, pa-
rietal, and temporal lobes, and a right ileopsoas mass. Bone marrow
was in remission, peripheral blood had 0.15% BCR/ABL by RT-
PCR. Dasatinib 40 mg po bid (1.5 mg/kg) was started. No other
chemotherapy was given. Clinical symptoms resolved after 6 days.
After 9 the CNS lesions became hypointense. Two large frontal
lobe masses, 1 parenchymal and 1 extra-axial, decreased in volume
from15 cc to 1.1 cc and CSF blasts to\1/ul. By day 23 the chlor-
omas had nearly resolved and CSF blasts were 0 by day 34. The
psoas mass resolved after 14 d. Plasma PK was measured 3 times,
and CSF 6 times at various points after dose. CNS response varied
with plasma level. Plasma levels after 7 d on 40 mg bid were slightly
lower than expected from adult data, (AUC 146 ng-h/ml, Cmax
40.4 ng-h/ml, and T1/2 2.2 hours). CSF levels were not detected
at any time point. On day 171 the patient developed disseminated
adenovirus and died on day 178. Post mortem showed no leukemia
in blood, marrow, or psoas muscle tissue by RT-PCR. There was
microscopic perivascular leukemia cell infiltration in the frontal
lobe, thalamus, and cerebellum. There was no evidence of CNS in-
fection.Conclusions: In this child plasma PK was similar to results
in adults. Ph1 leukemia in the CNS may respond to dasatinib de-
spite very low drug levels in the CSF.161
SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR ACUTE LEUKEMIAS RELAPSING AFTER FIRST TRANSPLANT IN PE-
DIATRIC PATIENTS
Martinez, C., Verneris, M.R., Weigel, B.J., Kumar, A., Baker, K.S.
University of Minnesota, Minneapolis, MN.
Recurrent leukemia is the most frequent indication for second al-
logeneic hematopoietic cell transplantation (HCT) in pediatric pa-
tients. However, there are few reports describing in detail the
overall survival in children who undergo a second stem cell trans-
plant procedure. We present our experience from the University
of Minnesota describing the outcome of 23 patients with either
acute lymphoblastic leukemia (ALL, n5 9) or acute myeloid leuke-
mia/myelodysplastic syndrome (AML/MDS, n 5 14) who had re-
lapsed after a first HCT and received a second allogeneic
transplant. The median age at the time of second transplant was
10 yrs for the AML/MDS patients and 6.8 yrs for the ALL patients.
All of the ALL patients were in complete remission at time of sec-
ond transplant, for the AML/MDS patients 6 were in remission
and 8 had active leukemia at the time of second HCT. The mean
time from first transplant to relapse for the ALL group was 406
days (range 0–729) and 619 days (range 20–4410) for the AML/
MDS group. Five patients received a second HCT from the same
donor source, 6 patients who had prior autologous HCT received
an unrelated donor (n5 5) or related donor (n5 1) for their second
HCT, and the remaining patients (n5 12) received a different allo-
geneic stem cell source. All of the patients except one patient with
AML/MDS received myeloablative conditioning with the second
HCT. Patients who received TBI with the first HCT were treated
with chemotherapy only conditioning regimens and those who had
not received TBI with the first HCT were treated with TBI based
regimens for the second HCT. The mean follow-up of the patients
with AML/MDS was 543 days (range 72–2109) and 708 days (range
23–2064) for the ALL group. The overall survival was 30% (n5 7),
four of fourteen survived in the AML/MDS group and three of nine
in the ALL group. Among the survivors the mean time from first
